Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03284970 · ClinicalTrials.gov registry record

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute.

Completed
Registry status
34
Enrollment target
1
Study location

NCT03284970: Completed study of Relapsing Remitting Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute.

NCT03284970 is a study of Relapsing Remitting Multiple Sclerosis that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 34 participants, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03284970, a study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by EMD Serono Research & Development Institute.

COMPLETED
Registry status
34 participants
Enrollment target
1
Study location

Study Summary

This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) counts and ratios in subjects aged 50 years and above with Relapsing-Remitting Multiple Sclerosis (RRMS).

Conditions Studied

Relapsing Remitting Multiple Sclerosis

Study Locations (1)

Massachusetts

  • Neurology Center of New England - Foxborough

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2017-08-23
Est. Completion 2018-05-11
EMD Serono Research & Development Institute

81 total trials

What the finished NCT03284970 record still lists

NCT03284970 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT03284970 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03284970 about?

NCT03284970 is a clinical study titled "Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes". This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) counts and ...

What is the current status of trial NCT03284970?

This trial is currently completed. The enrollment target is 34 participants. The study started on 2017-08-23. Estimated completion is 2018-05-11.

What conditions does trial NCT03284970 study?

This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.

Who is sponsoring clinical trial NCT03284970?

This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03284970 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Remitting Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03284970's enrollment target sits among peer trials

34 22nd of 25 higher than 4 of 25 other Relapsing Remitting Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03284970, the US trial registry maintained by the National Library of Medicine. NCT03284970 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.